Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NPX887 |
Synonyms | |
Therapy Description |
NPX887 is a monoclonal antibody that targets HHLA2 (B7-H7) and inhibits its interaction with KIR3DL3 while preserving the interaction with TMIGD2, which potentially enhances T and NK cell-mediated antitumor response (Ann Oncol (2024) 35 (Suppl_2): S708-709, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NPX887 | NPX-887|NPX 887 | NPX887 is a monoclonal antibody that targets HHLA2 (B7-H7) and inhibits its interaction with KIR3DL3 while preserving the interaction with TMIGD2, which potentially enhances T and NK cell-mediated antitumor response (Ann Oncol (2024) 35 (Suppl_2): S708-709, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06240728 | Phase I | NPX887 | A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 | Recruiting | USA | 0 |